Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 71.4% during trading on Tuesday . The stock traded as high as C$0.12 and last traded at C$0.12. 592,088 shares traded hands during mid-day trading, an increase of 516% from the average session volume of 96,162 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Performance
The company’s 50-day moving average price is C$0.08 and its 200 day moving average price is C$0.07. The stock has a market capitalization of C$10.45 million, a PE ratio of -6.00 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- How to Plot Fibonacci Price Inflection Levels
- 3 Stocks Helping to Bring AI to Healthcare
- Overbought Stocks Explained: Should You Trade Them?
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- 10 Best Airline Stocks to Buy
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
